ReviewJournal of food science2026
Microalgal Active Peptides: Advances in Preparation, Efficacy, and Mechanisms of Hypoglycemic Action.
Review in Journal of food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The escalating global prevalence of diabetes, marked by a troubling rise in younger demographics, imposes a substantial public health burden. Although current pharmacological interventions are effective, they are frequently constrained by adverse side effects and inherent pharmacological limitations. Microalgal bioactive peptides possess high protein content and sustainable production capacity. They exhibit a broad spectrum of bioactivities. Consequently, they are positioned as safe and effective candidates for glycemic regulation. Compared to conventional drugs, microalgal peptides present distinct advantages in sustainability and safety profiles. This review systematically consolidates current knowledge on microalgal hypoglycemic peptides, commencing with an overview of their resource superiority and potential for sustainable manufacturing. We then detail the evolving methodologies for peptide preparation, purification, and identification. A central focus is placed on elucidating their mechanisms of action, with particular emphasis on α-glucosidase inhibition, as revealed through advanced techniques such as molecular docking. Moreover, we critically assess the persistent challenges that currently impede full commercial translation. These include gaps in mechanistic understanding, bottlenecks in process optimization, and hurdles to industrial scale-up. Finally, future research directions aimed at overcoming these barriers are discussed. This review comprehensively synthesizes the research progress in this field, aiming to provide a reference for the development of microalgal-derived functional ingredients and to accelerate their translational application in diabetes intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.